Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 28:11:1324537.
doi: 10.3389/fcvm.2024.1324537. eCollection 2024.

Post-event follow-up costs in patients with atherosclerotic cardiovascular disease in Spain

Icíar Martínez López  1 , Jorge Francisco Gómez Cerezo  2 , José M Gámez  3   4   5 , Isabel Egocheaga Cabello  6 , Mar Castellanos  7 , Raquel Campuzano Ruiz  8 , Vivencio Barrios  9 , Vicente Pallarés-Carratalá  10   11 , José Manuel Rodríguez  11 , Nuria Morant Talamante  12 , Javier Parrondo  11 , José María Mostaza  13
Affiliations

Post-event follow-up costs in patients with atherosclerotic cardiovascular disease in Spain

Icíar Martínez López et al. Front Cardiovasc Med. .

Abstract

Introduction: Atherosclerotic cardiovascular disease (ASCVD) is one of the main causes of morbidity and mortality in developed countries and entails high resources use and costs for health systems. The risk of suffering future cardiovascular (CV) events and the consequent resources use is higher in those patients who have already had a previous cardiovascular event. The objective of the study was to determine the average annual cost of patients with a new or recurrent atherosclerotic CV event during the 2 years after the event.

Methodology: Retrospective observational study of electronic medical records of patients from the BIG-PAC® database (7 integrated health areas of 7 Autonomous Communities; n = 1.8 million). Patients with a new or recurrent episode of ASCVD (angina, acute myocardial infarction, transient ischemic attack, stroke, or peripheral arterial disease) between 1-Jan-2017 and 31-Dec-2018 were included. The resources use within two years of the diagnosis was estimated in order to estimate the average cost of patient follow-up.

Results: A total of 26,976 patients with an ASCVD episode were identified during the recruitment period; Out of them, 6,798 had a recurrent event during the follow-up period and 2,414 died. The average costs per patient were €11,171 during the first year and €9,944 during the second year.

Discussion: Patients with ASCVD represent a significant economic burden for the health system and for society. Despite the perception that drug costs in the follow-up of chronic patients imply a high percentage of the costs, these accounted for only one tenth of the total amount. Implementing preventive programs and increasing the control of cardiovascular risk factors may have a significant social and health impact by helping to reduce mortality and costs for the Spanish National Health System. The costs derived from pharmacological treatments were obtained from the NHS pricing nomenclator database (https://www.sanidad.gob.es/profesionales/nomenclator.do).

Keywords: atherosclerosis; cost of illness; electronic health records; hypercholesterolemia; observational study.

PubMed Disclaimer

Conflict of interest statement

NM, JMR and JP are employed by Novartis. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Study design.
See this image and copyright information in PMC

References

    1. WHO. Cardiovascular Diseases (CVDs). Updated June 2021 (2021). Available online at: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases... (November 23, 2022).
    1. OMS. Las 10 Principales Causas de Defunción (2020). Available online at: https://www.who.int/es/news-room/fact-sheets/detail/the-top-10-causes-of... (November 23, 2022)
    1. Estrategia en Salud Cardiovascular del Sistema Nacional de Salud (ESCAV). (2022; 133). Available online at: https://www.sanidad.gob.es/organizacion/sns/planCalidadSNS/pdf/ESCAV_Pen...
    1. Lindh M, Banefelt J, Fox KM, Hallberg S, Tai MH, Eriksson M, et al. Cardiovascular event rates in a high atherosclerotic cardiovascular disease risk population: estimates from Swedish population-based register data. Eur Heart J Qual Care Clin Outcomes. (2019) 5(3):225–32. 10.1093/ehjqcco/qcy058 - DOI - PMC - PubMed
    1. Borén J, Chapman MJ, Krauss RM, Packard CJ, Bentzon JF, Binder CJ, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European atherosclerosis society cConsensus panel . Eur Heart J, 2020. 41(24): p. 2313–30. 10.1093/eurheartj/ehz962 - DOI - PMC - PubMed